These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34958168)

  • 21. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
    Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
    Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
    Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C
    Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
    Papadimitrakopoulou VA; Mok TS; Han JY; Ahn MJ; Delmonte A; Ramalingam SS; Kim SW; Shepherd FA; Laskin J; He Y; Akamatsu H; Theelen WSME; Su WC; John T; Sebastian M; Mann H; Miranda M; Laus G; Rukazenkov Y; Wu YL
    Ann Oncol; 2020 Nov; 31(11):1536-1544. PubMed ID: 32861806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met.
    Majem M; Sullivan I; Viteri S; López-Vivanco G; Cobo M; Sánchez JM; García-González J; Garde J; Sampayo M; Martrat G; Malfettone A; Karachaliou N; Molina-Vila MA; Rosell R
    Eur J Cancer; 2021 Dec; 159():174-181. PubMed ID: 34763195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.
    Liu X; Hong L; Nilsson M; Hubert SM; Wu S; Rinsurongkawong W; Lewis J; Spelman A; Roth J; Swisher S; He Y; Jack Lee J; Fang B; Heymach JV; Zhang J; Le X
    Lung Cancer; 2020 Nov; 149():33-40. PubMed ID: 32956986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).
    Vaid AK; Gupta A; Momi G
    Int J Oncol; 2021 Feb; 58(2):171-184. PubMed ID: 33491758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
    White MN; Piotrowska Z; Stirling K; Liu SV; Banwait MK; Cunanan K; Sequist LV; Wakelee HA; Hausrath D; Neal JW
    Clin Lung Cancer; 2021 May; 22(3):201-209. PubMed ID: 33610453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for
    Shiozawa T; Numata T; Tamura T; Endo T; Kaburagi T; Yamamoto Y; Yamada H; Kikuchi N; Saito K; Inagaki M; Kurishima K; Funayama Y; Miyazaki K; Koyama N; Furukawa K; Nakamura H; Kikuchi S; Ichimura H; Sato Y; Sekine I; Satoh H; Hizawa N
    Anticancer Res; 2022 May; 42(5):2583-2590. PubMed ID: 35489768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy.
    Li X; Zhang D; Li B; Zou B; Wang S; Fan B; Li W; Yu J; Wang L
    Lung Cancer; 2021 Jan; 151():39-43. PubMed ID: 33296806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis.
    Xing P; Mu Y; Hao X; Wang Y; Li J
    Clin Transl Oncol; 2019 Oct; 21(10):1424-1431. PubMed ID: 30864019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of osimertinib for the treatment of previously EGFR TKI treated NSCLC patients: a meta-analysis.
    Li ZX; Zhao W; Sun Q; Tang MS; Xia QJ; Dong MS
    Clin Transl Oncol; 2020 Jun; 22(6):892-899. PubMed ID: 31538306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L).
    Haratake N; Hayashi H; Shimokawa M; Nakano Y; Azuma K; Oki M; Ota K; Yoshioka H; Sakamoto T; Yamamoto N; Nakagawa K; Seto T
    Clin Lung Cancer; 2022 May; 23(3):e257-e263. PubMed ID: 34887192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer.
    Auliac JB; Saboundji K; Andre M; Madelaine J; Quere G; Masson P; Vergnenegre A; Lamy R; Raymond S; Chiappa AM; Hauss PA; Fournel P; Corre R; Chouaid C
    Target Oncol; 2019 Jun; 14(3):307-314. PubMed ID: 31119481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
    Planchard D; Boyer MJ; Lee JS; Dechaphunkul A; Cheema PK; Takahashi T; Gray JE; Tiseo M; Ramalingam SS; Todd A; McKeown A; Rukazenkov Y; Ohe Y
    Clin Cancer Res; 2019 Apr; 25(7):2058-2063. PubMed ID: 30659024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis.
    Chen Y; Wang S; Zhang B; Zhao Y; Zhang L; Hu M; Zhang W; Han B
    Target Oncol; 2020 Jun; 15(3):337-345. PubMed ID: 32495159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
    Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
    Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival benefit of anlotinib in T790M-positive non-small-cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study.
    Chen Y; Liu H; Hu N; Wang Y; Yang Z; Zhang J; Han B
    Cancer Med; 2023 Aug; 12(15):15922-15932. PubMed ID: 37387596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.